After 15 Years, a New Fibromyalgia Drug Offers Real Pain Relief—Here's What You Need to Know

The Food and Drug Administration (FDA) approved Tonmya in August 2025, marking the first new fibromyalgia treatment in over 15 years. This sublingual tablet, taken once nightly before bed, showed significant pain reduction in clinical trials involving nearly 1,000 participants with fibromyalgia.

How Does Tonmya Work Differently?

Tonmya contains cyclobenzaprine hydrochloride, but it's delivered in a unique way. Unlike traditional pills that go through your stomach and liver, this tablet dissolves under your tongue for rapid absorption. This sublingual delivery bypasses first-pass liver metabolism, reducing production of norcyclobenzaprine—a long-lasting metabolite that can cause lingering side effects.

The medication targets multiple brain receptors involved in pain and sleep, including serotonin, adrenergic, histamine, and muscarinic receptors. By improving deep, restorative sleep quality, Tonmya addresses a core problem in fibromyalgia where poor sleep worsens pain and other symptoms.

What Did the Clinical Trials Show?

Two major Phase 3 trials called RELIEF and RESILIENT tested Tonmya's effectiveness. The RELIEF trial enrolled 503 adults with fibromyalgia, while RESILIENT included 457 participants. Both studies were double-blind, placebo-controlled trials lasting 14 weeks.

In the RELIEF trial, participants taking Tonmya experienced a significantly greater reduction in daily pain scores compared to those taking placebo. The treatment group saw an average pain reduction of 1.9 points, while the placebo group improved by 1.5 points on the pain scale.

The RESILIENT trial showed even stronger results, with Tonmya participants experiencing an average pain reduction of 1.8 points compared to 1.2 points for placebo—a statistically significant difference with over 99.9% certainty.

Beyond pain relief, participants also experienced improvements in several other areas:

• Sleep Quality: Daily sleep quality scores improved significantly compared to placebo
• Overall Function: Fibromyalgia Impact Questionnaire scores showed better daily functioning
• Fatigue Levels: Patient Reported Outcomes Measurement Information System fatigue scores improved
• Meaningful Pain Relief: More participants achieved at least a 30% reduction in pain compared to placebo

What Are the Side Effects?

Tonmya was generally well-tolerated across the clinical trials involving over 1,400 participants. The most common side effects were related to the sublingual delivery method and included oral numbness (23.4% vs 0.4% with placebo), abnormal taste (11.3% vs 0.9%), and mouth tingling (6.9% vs 0.9%). These local effects were described as transient and self-limited.

Systemic side effects occurred at similar rates to placebo, with the most common being COVID-19 infection (4.3% vs 3.1%), headache (3.0% vs 1.8%), and drowsiness (3.0% vs 1.3%). Other reported effects included fatigue, dry mouth, and mouth sores, all occurring in less than 5% of participants.

"The chronic pain of fibromyalgia is debilitating to every aspect of a person's life, including causing sleep disturbance and fatigue, all of which can negatively impact someone's ability to carry out their daily activities," said Sharon Waldrop, founder of the Fibromyalgia Association. "For over 15 years, this community has been underserved and waiting for new treatment options. This approval is a promising step forward and brings renewed hope to millions."

Is This a Game-Changer for Fibromyalgia?

The approval represents significant progress for the estimated 10 million Americans living with fibromyalgia. Prior to Tonmya, only three medications had FDA approval for fibromyalgia: pregabalin (approved 2007), duloxetine (2008), and milnacipran (2009). Many patients found inadequate relief with existing options.

However, experts emphasize that Tonmya isn't a cure-all. The improvements, while statistically significant, were sometimes modest. Some patients may not notice substantial changes, and long-term safety data is still being collected. The medication is likely to work best as part of a comprehensive treatment approach that includes gentle exercise, sleep hygiene, and management of other health conditions.

"For years, fibromyalgia patients have struggled with limited treatment options that often fall short. The availability of Tonmya marks a meaningful advancement by targeting neurotransmitters thought to be involved in fibromyalgia," said Dr. Andrea L. Chadwick from the University of Kansas Health System.

Tonmya is now available by prescription in the United States, though insurance coverage may take time to develop as with any new medication. The standard dosing starts at 2.8 mg nightly for the first two weeks, then increases to 5.6 mg nightly for those who tolerate the initial dose.